Orphazyme Interim Report First Half 2020 Presentation
Aug 26, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Kim Stratton, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Interim Report First Half 2020. The presentation will be followed by a Q&A session.
Orphazyme interim report first half 2020
Read moreCapital increase of 31,250 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
Jul 31, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Protein in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announces that a share capital increase has been registered with the Danish Business Authority as a result of the vesting and exercise of Matching Shares. A total of 31,250 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Matching Share of DKK 1.
Capital increase of 31 250 shares in orphazyme
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 29, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read moreOrphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C
Jul 20, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that it has completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
Orphazyme completes rolling submission of new drug
Read moreOrphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research
Jul 17, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announces that it will join The Michael J. Fox Foundation’s (MJFF) Parkinson’s Disease Research Tools Consortium. The group brings together experts from the medical community and industry to identify and develop new pre-clinical tools to address unmet research needs and accelerate experiments. Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).
Orphazyme to collaborate with the Michael J. Fox foundation
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 16, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme or their closely associated persons.
Reporting of transactions in orphazymes shares made
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 15, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreCapital increase of 3,451 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Jul 7, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Proteins in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that a share capital increase has been registered with the Danish Business Authority as a result of the exercise of Restricted Share Units by board members. A total of 3,451 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Restricted Share Unit of DKK 61.1895.
Capital increase of 3 451 shares in Orphazyme
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 3, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreNew share-based incentive program
Jul 1, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Company has introduced a new share-based incentive program (the “LTIP”) for 2020. The LTIP has been implemented in accordance with Orphazyme’s Remuneration Policy adopted at Orphazyme’s annual general meeting on March 26, 2020.
Read more